| Michael Czurylo, DPM | |
|
2075 Barkley Blvd Ste 220, Bellingham, WA 98226-6614 | |
| (360) 933-4813 | |
| (360) 933-4526 |
| Full Name | Michael Czurylo |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 8 Years |
| Location | 2075 Barkley Blvd Ste 220, Bellingham, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588118806 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 135.000919 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Foot And Ankle Institute Pllc | 5991032013 | 2 |
News Archive
Anti-NMDA receptor (NMDAR) encephalitis was first reported to develop in female young adults with ovarian teratoma.
Despite known risks and recommendations for protective equipment, many people are still affected with asthma after exposure to chemicals at work. This is the finding of an international study of 13,000 people carried out at the Sahlgrenska Academy, University of Gothenburg, Sweden.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.
A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer's disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer's disease.
› Verified 9 days ago
| Provider Name | Northwest Foot And Ankle Institute Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1649732017 PECOS PAC ID: 5991032013 Enrollment ID: O20190813002013 |
News Archive
Anti-NMDA receptor (NMDAR) encephalitis was first reported to develop in female young adults with ovarian teratoma.
Despite known risks and recommendations for protective equipment, many people are still affected with asthma after exposure to chemicals at work. This is the finding of an international study of 13,000 people carried out at the Sahlgrenska Academy, University of Gothenburg, Sweden.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.
A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer's disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer's disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Czurylo, DPM 2075 Barkley Blvd Ste 220, Bellingham, WA 98226-6614 Ph: (360) 933-4813 | Michael Czurylo, DPM 2075 Barkley Blvd Ste 220, Bellingham, WA 98226-6614 Ph: (360) 933-4813 |
News Archive
Anti-NMDA receptor (NMDAR) encephalitis was first reported to develop in female young adults with ovarian teratoma.
Despite known risks and recommendations for protective equipment, many people are still affected with asthma after exposure to chemicals at work. This is the finding of an international study of 13,000 people carried out at the Sahlgrenska Academy, University of Gothenburg, Sweden.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.
Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.
A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer's disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer's disease.
› Verified 9 days ago
Geoffrey J Mcallister, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 520 Birchwood Ave Ste A, Bellingham, WA 98225 Phone: 360-734-3668 Fax: 360-676-8941 | |
Bellingham Foot Care Center, Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 1600 F St, Bellingham, WA 98225 Phone: 360-733-3710 Fax: 360-733-7906 | |
Dr. Mark Whitman Sheafor, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3120 Squalicum Pkwy Ste 2, Bellingham, WA 98225 Phone: 360-647-0557 Fax: 360-733-2892 | |
Dr. Michael Alan Sherwin, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 234 36th St, Bellingham, WA 98225 Phone: 360-738-9797 Fax: 360-738-9809 | |
Family Foot Care, P.s. Podiatrist Medicare: Medicare Enrolled Practice Location: 234 36th St, Bellingham, WA 98225 Phone: 360-738-9797 | |
Northwest Foot And Ankle Institute Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 2075 Barkley Blvd Ste 220, Bellingham, WA 98226 Phone: 224-688-9328 |